Cantor Fitzgerald Comments on Codexis FY2026 Earnings

Codexis, Inc. (NASDAQ:CDXS - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Codexis in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of ($0.48) per share for the year. The consensus estimate for Codexis' current full-year earnings is ($0.77) per share.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The business had revenue of $7.54 million during the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%.

Separately, Wall Street Zen upgraded Codexis to a "sell" rating in a research report on Friday, May 16th.

Codexis Stock Performance

NASDAQ:CDXS traded up $0.06 during midday trading on Tuesday, hitting $2.44. The company's stock had a trading volume of 622,329 shares, compared to its average volume of 706,077. Codexis has a fifty-two week low of $1.90 and a fifty-two week high of $6.08. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The firm has a market cap of $202.14 million, a P/E ratio of -2.80 and a beta of 2.52. The firm's 50 day moving average is $2.32 and its 200-day moving average is $3.56.

Institutional Investors Weigh In On Codexis

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Codexis by 7.5% in the fourth quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company's stock worth $21,292,000 after acquiring an additional 311,082 shares during the last quarter. Telemark Asset Management LLC boosted its stake in Codexis by 11.3% during the 4th quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company's stock worth $14,310,000 after purchasing an additional 303,589 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Codexis by 0.5% during the 4th quarter. Ameriprise Financial Inc. now owns 2,399,650 shares of the biotechnology company's stock worth $11,446,000 after purchasing an additional 12,625 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Codexis by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company's stock worth $8,853,000 after buying an additional 211,475 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its position in shares of Codexis by 18.6% in the fourth quarter. Nuveen Asset Management LLC now owns 1,812,345 shares of the biotechnology company's stock valued at $8,645,000 after buying an additional 283,760 shares during the last quarter. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.